REG - ValiRx PLC - Clinical Phase Development Update <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

19/11/2015 10:41

RNS Number : 2870G
ValiRx PLC
19 November 2015
ValiRx Plc (AIM: VAL)
("ValiRx" or "the Company")
Clinical Phase Development Update re VAL201 and VAL401
London, UK., 19 November 2015 - ValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine, today announces that its leadcompound, VAL201, is completing the dose escalation part of its Phase l/ll Clinical Trial. 
VAL201 demonstrates safety and tolerability and no significant adverse effects have been recorded, confirming the previously announced First-In-Human results. Other measurements taken so far are comparable to the positive results seen pre-clinically.
For the expansion phase, further Clinical Trial Centres, in addition to UCLH, are being opened in order to extend the availability of test patients. This phase will continue during 2016 as described in the approved protocol. During the latter part of the trial, the primary and secondary outcomes will be further refined and results relating to the applicability and efficacy of the treatment will be expanded.
Public details of the trial can be found on the website www.Clinicaltrials.gov.
VAL401
Following on from the earlier announcement of the establishment of a Clinical Trial Contract with Clinical Accelerator, the protocols and associated files have been drafted for submission to the appropriate regulatory authorities and ethics committees. 
The trial is to be entitled: "A Phase II study to assess the efficacy, safety and tolerability of VAL401 in the treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapeutic regimen". 
The preparatory clinical process is proceeding according to timetable and it is anticipated that the trial will begin recruitment during the earlier part of 2016.


***ENDS***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka
www.valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson



Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking) 

Peckwater PR
Tel: +44 (0) 7879 458 364
Tarquin Edwards
tarquin.edwards@peckwaterpr.co.uk
Notes for Editors 
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company has undertaken todevelop a novel and groundbreaking class of therapeutics across a number offields in oncology and has taken its lead compound, Val201, into Phase I/IIclinicaltrials. The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases.
It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimising financial exposure andrunning a set of projects todefined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through thefollowing divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technologylater in the year to strengthen the portfolio.
3. ValiSeek is a joint venturebetween ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentiallyother indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RESFFUFSUFISEDF